- Home
- MDGL vs MRUS Comparison
MDGL vs MRUS Comparison
Compare MDGL & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- MRUS
- Stock Information
- Founded
- MDGL 2011
- MRUS 2003
- Country
- MDGL United States
- MRUS Netherlands
- Employees
- MDGL N/A
- MRUS N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- MRUS Health Care
- Exchange
- MDGL Nasdaq
- MRUS Nasdaq
- Market Cap
- MDGL 6.1B
- MRUS 5.1B
- IPO Year
- MDGL N/A
- MRUS 2016
- Fundamental
- Price
- MDGL $424.95
- MRUS $67.41
- Analyst Decision
- MDGL Strong Buy
- MRUS Strong Buy
- Analyst Count
- MDGL 10
- MRUS 13
- Target Price
- MDGL $474.67
- MRUS $90.92
- AVG Volume (30 Days)
- MDGL 383.6K
- MRUS 591.5K
- Earning Date
- MDGL 10-30-2025
- MRUS 10-30-2025
- Dividend Yield
- MDGL N/A
- MRUS N/A
- EPS Growth
- MDGL N/A
- MRUS N/A
- EPS
- MDGL N/A
- MRUS N/A
- Revenue
- MDGL $515,547,000.00
- MRUS $56,228,000.00
- Revenue This Year
- MDGL $394.12
- MRUS $57.42
- Revenue Next Year
- MDGL $57.74
- MRUS $0.23
- P/E Ratio
- MDGL N/A
- MRUS N/A
- Revenue Growth
- MDGL 3421.98
- MRUS 59.77
- 52 Week Low
- MDGL $200.63
- MRUS $33.19
- 52 Week High
- MDGL $457.16
- MRUS $70.65
- Technical
- Relative Strength Index (RSI)
- MDGL 58.68
- MRUS 53.75
- Support Level
- MDGL $425.00
- MRUS $65.74
- Resistance Level
- MDGL $440.90
- MRUS $70.65
- Average True Range (ATR)
- MDGL 14.17
- MRUS 2.49
- MACD
- MDGL -4.03
- MRUS -0.02
- Stochastic Oscillator
- MDGL 28.61
- MRUS 59.00
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.